TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32674250
Drug: 80 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 g/d oatmeal
Study: 32674250
Drug: 80 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 g/d refined white rice
Study: 33991868
Drug: Mobile application
Normalized name: Mahana IBS CBT Mobile Application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile application for treatment adherence and symptom management
Study: 36008246
Drug: Standard conservative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard conservative treatments
Study: 34174551
Drug: High nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High nicotine (0.5 mg) with low menthol (0.5%)
Study: 34174551
Drug: Low nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low nicotine (0.25 mg) with low menthol (0.5%)
Study: 34174551
Drug: Saline control
Normalized name: GLYCERIN 0.53 g in 1 mL CUTANEOUS INJECTION [Glycerol-Saline Control]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline control (0.0 mg) with low menthol (0.5%)
Study: 34174551
Drug: High nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High nicotine (0.5 mg) with saline control (0.0%)
Study: 34174551
Drug: Low nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low nicotine (0.25 mg) with saline control (0.0%)
Study: 35320813
Drug: Traditional swallowing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional swallowing rehabilitation treatment
Study: 32224489
Drug: Affect-focused internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Affect-focused internet-based psychodynamic therapy (IPDT) for 8 weeks
Study: 34582037
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of ropivacaine 0.2% at 6 ml/h
Study: 34582037
Drug: Programmed, intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmed, intermittent boluses of ropivacaine 0.2% at 10 ml every 8th hour
Study: 34174225
Drug: Exoskeleton-Assisted Anthropomorphic
Normalized name: Corallium rubrum exoskeleton preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exoskeleton-Assisted Anthropomorphic Movement Training (EAMT) therapy
Study: 34174225
Drug: Conventional upper
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional upper limb therapy
Study: 33597056
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g milk protein (MILK)
Study: 36170964
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g plant-derived protein blend (PLANT-BLEND) combining 15 g wheat, 7.5 g corn, and 7.5 g pea protein
Study: 32557601
Drug: Ribociclib 400
Normalized name: ribociclib 400 MG / letrozole 2.5 MG Daily Dose Carton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib 400 mg single-dose
Study: 32557601
Drug: Multiple 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple 400 mg ribociclib doses
Study: 32557601
Drug: Multiple 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple 600 mg ribociclib doses
Study: 32557601
Drug: Ritonavir with
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir with ribociclib 600 mg multiple doses
Study: 33783964
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (Lantus; IGlar)
Study: 35751029
Drug: Remifentanil (Ce
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (Ce of 4.0 ng.ml−1 during TCI of 3.5 μg.ml−1 propofol) in PD patients
Study: 35751029
Drug: Remifentanil (Ce
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (Ce of 4.0 ng.ml−1 during TCI of 3.5 μg.ml−1 propofol) in NPD patients
Study: 34120613
Drug: Daily intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intake of alcohol
Study: 34411872
Drug: Rational Emotive
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rational Emotive Behavior Therapy (REBT), 8-week group-based counseling sessions
Study: 39028360
Drug: Closed-loop insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop insulin delivery
Study: 33532993
Drug: PIEB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIEB with 2.5 mL of bupivacaine 0.25% plus fentanyl 8 µg·mL‐1 at 30 min interval
Study: 33532993
Drug: PIEB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIEB with 2.5 mL of bupivacaine 0.25% plus fentanyl 8 µg·mL‐1 at more than 30 min interval
Study: 35351058
Drug: Patient empowerment
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient empowerment project for training of bladder preparation
Study: 35351058
Drug: Pilot trial
Normalized name: Picot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilot trial investigating safety of PSMA-PET for focal dose escalation RT
Study: 35351058
Drug: Urethral sparing
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urethral sparing in focal dose escalation
Study: 35089999
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea containing 550 mg mulberry leaf extract (MLE), 3 times a day for 4 weeks
Study: 32854125
Drug: Immediate operative
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate operative therapy
Study: 35098659
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids or low-dose antipsychotic medication (fast-fail option)
Study: 33019891
Drug: Cholecalciferol 1000-2000
Normalized name: cholecalciferol 2000 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 1000-2000 IU daily or 50000 IU weekly until vitamin D levels >20 ng/mL (group IIa) or >30 ng/mL (group IIb)
Study: 33019891
Drug: Cholecalciferol 1000-2000
Normalized name: cholecalciferol 2000 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 1000-2000 IU daily or 50000 IU weekly until vitamin D levels >20 ng/mL (group IIa)
Study: 32898192
Drug: Aceclofenac 100
Normalized name: aceclofenac 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aceclofenac 100 mg tablet formulation (F-15)
Study: 34723864
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (5 mg/kg ideal body weight)
Study: 34674610
Drug: Standardized extract
Normalized name: Spring Valley Olive Leaf Standardized Extract 150mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized extract of Calendula officinalis L. (SEC)
Study: 32187097
Drug: Local multimodal
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local multimodal drug injection (ropivacaine 10 mL, morphine 5 mL, ceftezole 5 mL, normal saline 5 mL)
Study: 32187097
Drug: Local multimodal
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local multimodal drug injection
Study: 33935137
Drug: New drug
Normalized name: varicella zoster immune globulin (Investigational New Drug)
Approvals — FDA: no, EMA: no, PMDA: no
Description: New drug comorbidity index
Study: 33962902
Drug: Daily delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily delivery of a single whole egg per day added to local standard nutrition care for 6 months
Study: 33165153
Drug: Multimodal neuroimaging-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal neuroimaging-based customized TMS treatment
Study: 36457068
Drug: Esketamine 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine 0.2 mg/kg IV before induction of anesthesia
Study: 34186473
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of medications including opioids and other medications inconsistent with national (NICE) guidance
Study: 32107712
Drug: Gefitinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib (250 mg daily)
Study: 35690073
Drug: 3‐weekly carboplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐weekly carboplatin AUC5 or AUC6 and 3‐weekly paclitaxel 175 mg/m2 (control; group 1)
Study: 35690073
Drug: 3‐weekly carboplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐weekly carboplatin AUC5 or AUC6 and weekly paclitaxel 80 mg/m2 (group 2)
Study: 35690073
Drug: Weekly carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly carboplatin AUC2 and weekly paclitaxel 80 mg/m2 (group 3)
Study: 32170964
Drug: Initial cohort
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial cohort (no treatment)
Study: 37481816
Drug: Optimal Medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal Medical Therapy (OMT)
Study: 34480787
Drug: USPIO injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: USPIO injection (5.6 mg/kg)
Study: 34480787
Drug: USPIO injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: USPIO injection (16.8 mg/kg)
Study: 34480787
Drug: USPIO injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: USPIO injection (56 mg/kg)
Study: 34812502
Drug: Baseline GDF15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline GDF15 >1350 pg/mL
Study: 34812502
Drug: AFP >5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFP >5 ng/mL
Study: 32511015
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy interventions for anxiety
Study: 32511015
Drug: Pre-treatment accommodation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment accommodation
Study: 36774994
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of ranibizumab
Study: 33814126
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) 10 mg/day
Study: 36008795
Drug: Myofunctional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myofunctional treatment (MB-M group)
Study: 36008795
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (MB-N group)
Study: 36008795
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (NB group)
Study: 35295986
Drug: Liothyronine 0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liothyronine 0.7 mcg/kg
Study: 35295986
Drug: Levothyroxine 0.86
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine 0.86 mcg/kg
Study: 34898075
Drug: Linshu Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linshu Decoction (1 dose bid) combined with levofloxacin (0.1 g bid)
Study: 34898075
Drug: Levofloxacin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (0.1 g bid)
Study: 33407619
Drug: Peg-interferon treatment
Normalized name: PEG-Interferon alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peg-interferon treatment
Study: 32220093
Drug: Type 2
Normalized name: Type 2 H
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type 2 statins (atorvastatin, rosuvastatin)
Study: 32745598
Drug: Family Focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family Focused Therapy for High-Risk Youth (FFT-HR)
Study: 33725579
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clinical, MRI, and pathology features
Study: 34609956
Drug: Directly Observed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directly Observed Treatment (DOT)
Study: 32402630
Drug: Complex decongestive
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex decongestive therapy (CDT) combined with rehabilitation exercise
Study: 37074613
Drug: Remdesivir (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remdesivir (200 mg on day 1 and 100 mg on days 2 and 3)
Study: 32278106
Drug: Interrupted Subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interrupted Subcutaneous Suture Group
Study: 33159033
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (IN‐OT) treatment (24 IU daily for 4 weeks)
Study: 33159033
Drug: Multiple-dose IN‐OT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose IN‐OT treatment (24 IU daily for 4 weeks)
Study: 32991355
Drug: Carvedilol 12.5
Normalized name: carvedilol 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 12.5 mg/d
Study: 32978034
Drug: Enriched Acceptance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enriched Acceptance and Commitment Therapy (EnACT)
Study: 33678038
Drug: Multicomponent intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent intervention administered by an unblinded nurse falls care manager
Study: 35313936
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of 0.25% bupivacaine (total 50 mg) for bilateral ultrasound-guided rectus sheath block (URSB)
Study: 33580845
Drug: Glutamine (4
Normalized name: N5-((2E)-((2-(((2,3-bis(omega-methoxypoly(oxyethylene))propoxy)carbonyl)amino)ethoxy)imino)ethyl)glutamine (43000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (4 g twice daily)
Study: 33580845
Drug: Placebo (glycine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (glycine, 4 g twice daily)
Study: 33584534
Drug: Gabby (online
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabby (online conversational agent)
Study: 35357881
Drug: Propranolol (β-blocker)
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol (β-blocker)
Study: 37615850
Drug: Ramipril 2.5
Normalized name: ramipril 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 2.5 mg daily
Study: 35381657
Drug: Psychological suggestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological suggestion combined with rational diet therapy
Study: 34313371
Drug: Ripretinib 150
Normalized name: Ripretinib
DrugBank: Ripretinib (DB14840)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ripretinib 150 mg b.i.d.
Study: 33037609
Drug: Medium NaCl
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium NaCl (0.4 g/100 mL) + 29 mM MSG
Study: 33037609
Drug: Low NaCl
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low NaCl (0.2 g/100 mL) + 29 mM MSG
Study: 33037609
Drug: Control broth
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control broth (0 g NaCl, 0 g MSG)
Study: 33037609
Drug: High NaCl
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High NaCl broth (0.8 g/100 mL)
Study: 33037609
Drug: Medium NaCl
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium NaCl (0.4 g/100 mL)
Study: 33037609
Drug: Low NaCl
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low NaCl (0.2 g/100 mL)
Study: 33718425
Drug: Insulin-resistant group
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-resistant group
Study: 33718425
Drug: Insulin-sensitive group
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-sensitive group
Study: 33938708
Drug: Tacrolimus 0.1%
Normalized name: TACROLIMUS 0.1% OINT,TOP
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus 0.1% ointment after dermabrasion
Study: 33938708
Drug: Dinoprostone gel
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dinoprostone gel after dermabrasion
Study: 34670544
Drug: Microthreaded implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microthreaded implants
Study: 34670544
Drug: Threaded implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Threaded implants
Study: 35272779
Drug: Intravascular ultrasound
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravascular ultrasound (IVUS) guidance with drug-coated balloons
Study: 35272779
Drug: Angiographic guidance
Normalized name: Andrographis paniculata top extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiographic guidance with drug-coated balloons
Study: 36894938
Drug: Dulaglutide 4.5
Normalized name: DULAGLUTIDE 4.5MG/0.5ML INJ PEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulaglutide 4.5 mg
Study: 35546790
Drug: Dulaglutide 3.0
Normalized name: Dulaglutide 3.0 mg in 0.5 mL SUBCUTANEOUS INJECTION, SOLUTION [Trulicity]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulaglutide 3.0 mg
Study: 34386735
Drug: Dapagliflozin 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 50 mg
Study: 34281014
Drug: Live-Performed Music
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live-Performed Music Therapy (LPMT)
Study: 33377343
Drug: CO2 fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2 fractional laser treatment
Study: 36380186
Drug: B. clausii
DrugBank: Bacillus clausii (DB16537)
Approvals — FDA: no, EMA: no, PMDA: no
Description: B. clausii (oral suspension, total dose 4 billion spores/day)
Study: 32224739
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (TXA) at a dose of 15 mg/kg
Study: 34932280
Drug: Mexidol intravenously
Normalized name: Brexidol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexidol intravenously 500 mg once daily for 14 days, followed by Mexidol FORTE 250 - 250 mg 3 times a day orally for 60 days
Study: 34399839
Drug: Polyvinyl chloride
Normalized name: POLYVINYL CHLORIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyvinyl chloride foil containing an integrated silver-based agent (2% silver ions) applied to high-touch surfaces
Study: 33377959
Drug: Goal-directed fluid
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed fluid therapy
Study: 36378780
Drug: Udenafil (87.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Udenafil (87.5 mg po BID)
Study: 32795214
Drug: Ongoing medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongoing medicine randomized controlled trials (RCTs) in Europe
Study: 32795214
Drug: Ongoing medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongoing medicine randomized controlled trials (RCTs) in the USA
Study: 33594278
Drug: Scheduled low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Scheduled low-dose memory (CD45RA-depleted) donor lymphocyte infusion (mDLI)
Study: 33086387
Drug: Intra-arterial short-term
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-arterial short-term infusion chemotherapy via angiocatheters or implanted arterial port catheters, infusion time of 7 to 12 minutes.
Study: 34958721
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline (5.8%) injection
Study: 34958721
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline (0.9%) injection
Study: 34704715
Drug: Medial branch
Normalized name: Machilus thunbergii branch extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medial branch block (MBB) during PKP surgery, injection of lidocaine and budesonide
Study: 34704715
Drug: Non-MBB group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-MBB group (normal saline injection during PKP surgery)
Study: 35416374
Drug: Two cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two cycles of induction chemotherapy with platinum and docetaxel (TP) plus a Bcl‐2 inhibitor
Study: 35416374
Drug: Single cycle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single cycle induction chemotherapy with platinum and 5‐flurouracil (PF)
Study: 35781776
Drug: Intensive medical
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive medical therapy
Study: 32758152
Drug: Manufactured UDCA
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manufactured UDCA (300 mg tablets and capsules)
Study: 37699636
Drug: Oral hydration
Normalized name: terpin hydrate Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hydration
Study: 85068751
Drug: Bromocriptine 2.5
Normalized name: bromocriptine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine 2.5 + 2.5 mg
Study: 85068751
Drug: Ethanol (1
Normalized name: ALCOHOL 95 mL in 100 mL TOPICAL SOLUTION [95% Ethanol (190 Proof)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (1 g/kg)
Study: 35523116
Drug: Cissus quadrangularis
Normalized name: Cissus quadrangularis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cissus quadrangularis 1.6 g/day (CQ1.6)
Study: 35523116
Drug: Cissus quadrangularis
Normalized name: Cissus quadrangularis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cissus quadrangularis 1.2 g/day (CQ1.2)
Study: 34978133
Drug: PRP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP treatment (all groups)
Study: 32621657
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid injections using a stamp-type microneedle (Dermashine balance)
Study: 38394657
Drug: Leukocyte- and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukocyte- and platelet-rich fibrin (L-PRF)
Study: 36151016
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no L-PRF)
Study: 37778356
Drug: Maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance treatment